nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—stomach cancer	0.462	0.788	CbGaD
Gliclazide—ALB—stomach cancer	0.124	0.212	CbGaD
Gliclazide—ALB—Irinotecan—stomach cancer	0.0334	0.258	CbGbCtD
Gliclazide—ALB—Fluorouracil—stomach cancer	0.0321	0.247	CbGbCtD
Gliclazide—CYP2C9—Capecitabine—stomach cancer	0.0292	0.225	CbGbCtD
Gliclazide—ALB—Methotrexate—stomach cancer	0.0177	0.136	CbGbCtD
Gliclazide—CYP2C9—Fluorouracil—stomach cancer	0.0173	0.133	CbGbCtD
Gliclazide—VEGFA—smooth muscle tissue—stomach cancer	0.00185	0.0848	CbGeAlD
Gliclazide—ALB—gall bladder—stomach cancer	0.00175	0.0802	CbGeAlD
Gliclazide—VEGFA—pancreas—stomach cancer	0.00171	0.0784	CbGeAlD
Gliclazide—KCNJ11—hematopoietic system—stomach cancer	0.0015	0.0689	CbGeAlD
Gliclazide—VEGFA—bone marrow—stomach cancer	0.00135	0.0617	CbGeAlD
Gliclazide—KCNJ11—pancreas—stomach cancer	0.00122	0.0561	CbGeAlD
Gliclazide—ABCC8—smooth muscle tissue—stomach cancer	0.00122	0.0559	CbGeAlD
Gliclazide—ABCC8—pancreas—stomach cancer	0.00113	0.0516	CbGeAlD
Gliclazide—VEGFA—liver—stomach cancer	0.00109	0.0499	CbGeAlD
Gliclazide—KCNJ11—lymphoid tissue—stomach cancer	0.00106	0.0485	CbGeAlD
Gliclazide—KCNJ11—endocrine gland—stomach cancer	0.000863	0.0396	CbGeAlD
Gliclazide—VEGFA—lymph node—stomach cancer	0.000834	0.0382	CbGeAlD
Gliclazide—CYP2C19—hematopoietic system—stomach cancer	0.000797	0.0366	CbGeAlD
Gliclazide—ABCC8—endocrine gland—stomach cancer	0.000795	0.0364	CbGeAlD
Gliclazide—CYP2C9—hematopoietic system—stomach cancer	0.000618	0.0283	CbGeAlD
Gliclazide—KCNJ11—lymph node—stomach cancer	0.000596	0.0274	CbGeAlD
Gliclazide—CYP2C19—digestive system—stomach cancer	0.000554	0.0254	CbGeAlD
Gliclazide—ALB—liver—stomach cancer	0.000513	0.0235	CbGeAlD
Gliclazide—Glipizide—PPARG—stomach cancer	0.000487	0.845	CrCbGaD
Gliclazide—CYP2C19—endocrine gland—stomach cancer	0.000458	0.021	CbGeAlD
Gliclazide—CYP2C9—digestive system—stomach cancer	0.00043	0.0197	CbGeAlD
Gliclazide—CYP2C19—liver—stomach cancer	0.000413	0.0189	CbGeAlD
Gliclazide—ALB—lymph node—stomach cancer	0.000393	0.018	CbGeAlD
Gliclazide—CYP2C9—endocrine gland—stomach cancer	0.000355	0.0163	CbGeAlD
Gliclazide—CYP2C9—liver—stomach cancer	0.00032	0.0147	CbGeAlD
Gliclazide—Skin disorder—Capecitabine—stomach cancer	9.42e-05	0.000601	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—stomach cancer	9.4e-05	0.0006	CcSEcCtD
Gliclazide—Hyperhidrosis—Capecitabine—stomach cancer	9.38e-05	0.000598	CcSEcCtD
Gliclazide—Oedema peripheral—Epirubicin—stomach cancer	9.37e-05	0.000598	CcSEcCtD
Gliclazide—Hypotension—Docetaxel—stomach cancer	9.36e-05	0.000597	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—stomach cancer	9.27e-05	0.000591	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—stomach cancer	9.25e-05	0.00059	CcSEcCtD
Gliclazide—Vomiting—Irinotecan—stomach cancer	9.22e-05	0.000588	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—stomach cancer	9.2e-05	0.000587	CcSEcCtD
Gliclazide—Dizziness—Fluorouracil—stomach cancer	9.18e-05	0.000586	CcSEcCtD
Gliclazide—Visual impairment—Epirubicin—stomach cancer	9.17e-05	0.000585	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—stomach cancer	9.15e-05	0.000584	CcSEcCtD
Gliclazide—Rash—Irinotecan—stomach cancer	9.14e-05	0.000583	CcSEcCtD
Gliclazide—Dermatitis—Irinotecan—stomach cancer	9.13e-05	0.000582	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Docetaxel—stomach cancer	9.13e-05	0.000582	CcSEcCtD
Gliclazide—Chills—Methotrexate—stomach cancer	9.12e-05	0.000582	CcSEcCtD
Gliclazide—Headache—Irinotecan—stomach cancer	9.08e-05	0.000579	CcSEcCtD
Gliclazide—Hypotension—Capecitabine—stomach cancer	9.07e-05	0.000578	CcSEcCtD
Gliclazide—Insomnia—Docetaxel—stomach cancer	9.06e-05	0.000578	CcSEcCtD
Gliclazide—Paraesthesia—Docetaxel—stomach cancer	9e-05	0.000574	CcSEcCtD
Gliclazide—Erythema multiforme—Epirubicin—stomach cancer	9e-05	0.000574	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—stomach cancer	8.96e-05	0.000572	CcSEcCtD
Gliclazide—Glyburide—ALB—stomach cancer	8.95e-05	0.155	CrCbGaD
Gliclazide—Dyspnoea—Docetaxel—stomach cancer	8.93e-05	0.00057	CcSEcCtD
Gliclazide—Somnolence—Docetaxel—stomach cancer	8.91e-05	0.000568	CcSEcCtD
Gliclazide—Mental disorder—Methotrexate—stomach cancer	8.91e-05	0.000568	CcSEcCtD
Gliclazide—Eye disorder—Epirubicin—stomach cancer	8.89e-05	0.000567	CcSEcCtD
Gliclazide—Tinnitus—Epirubicin—stomach cancer	8.87e-05	0.000566	CcSEcCtD
Gliclazide—Malnutrition—Methotrexate—stomach cancer	8.85e-05	0.000564	CcSEcCtD
Gliclazide—Erythema—Methotrexate—stomach cancer	8.85e-05	0.000564	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Capecitabine—stomach cancer	8.84e-05	0.000564	CcSEcCtD
Gliclazide—Flushing—Epirubicin—stomach cancer	8.83e-05	0.000563	CcSEcCtD
Gliclazide—Vomiting—Fluorouracil—stomach cancer	8.83e-05	0.000563	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—stomach cancer	8.83e-05	0.000563	CcSEcCtD
Gliclazide—Dyspepsia—Docetaxel—stomach cancer	8.82e-05	0.000563	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—stomach cancer	8.8e-05	0.000561	CcSEcCtD
Gliclazide—Insomnia—Capecitabine—stomach cancer	8.78e-05	0.00056	CcSEcCtD
Gliclazide—Hypoaesthesia—Doxorubicin—stomach cancer	8.76e-05	0.000559	CcSEcCtD
Gliclazide—Rash—Fluorouracil—stomach cancer	8.75e-05	0.000558	CcSEcCtD
Gliclazide—Dermatitis—Fluorouracil—stomach cancer	8.75e-05	0.000558	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—stomach cancer	8.74e-05	0.000557	CcSEcCtD
Gliclazide—Paraesthesia—Capecitabine—stomach cancer	8.71e-05	0.000556	CcSEcCtD
Gliclazide—Headache—Fluorouracil—stomach cancer	8.7e-05	0.000555	CcSEcCtD
Gliclazide—Oedema peripheral—Doxorubicin—stomach cancer	8.67e-05	0.000553	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Docetaxel—stomach cancer	8.65e-05	0.000552	CcSEcCtD
Gliclazide—Dyspnoea—Capecitabine—stomach cancer	8.65e-05	0.000552	CcSEcCtD
Gliclazide—Fatigue—Docetaxel—stomach cancer	8.64e-05	0.000551	CcSEcCtD
Gliclazide—Nausea—Irinotecan—stomach cancer	8.61e-05	0.000549	CcSEcCtD
Gliclazide—Pain—Docetaxel—stomach cancer	8.57e-05	0.000547	CcSEcCtD
Gliclazide—Constipation—Docetaxel—stomach cancer	8.57e-05	0.000547	CcSEcCtD
Gliclazide—Back pain—Methotrexate—stomach cancer	8.56e-05	0.000546	CcSEcCtD
Gliclazide—Dyspepsia—Capecitabine—stomach cancer	8.54e-05	0.000545	CcSEcCtD
Gliclazide—Chills—Epirubicin—stomach cancer	8.54e-05	0.000544	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—stomach cancer	8.5e-05	0.000542	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—stomach cancer	8.48e-05	0.000541	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Capecitabine—stomach cancer	8.38e-05	0.000534	CcSEcCtD
Gliclazide—Fatigue—Capecitabine—stomach cancer	8.36e-05	0.000533	CcSEcCtD
Gliclazide—Mental disorder—Epirubicin—stomach cancer	8.33e-05	0.000532	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—stomach cancer	8.32e-05	0.000531	CcSEcCtD
Gliclazide—Pain—Capecitabine—stomach cancer	8.3e-05	0.000529	CcSEcCtD
Gliclazide—Constipation—Capecitabine—stomach cancer	8.3e-05	0.000529	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—stomach cancer	8.28e-05	0.000528	CcSEcCtD
Gliclazide—Erythema—Epirubicin—stomach cancer	8.28e-05	0.000528	CcSEcCtD
Gliclazide—Feeling abnormal—Docetaxel—stomach cancer	8.26e-05	0.000527	CcSEcCtD
Gliclazide—Nausea—Fluorouracil—stomach cancer	8.25e-05	0.000526	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—stomach cancer	8.23e-05	0.000525	CcSEcCtD
Gliclazide—Ill-defined disorder—Methotrexate—stomach cancer	8.21e-05	0.000524	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—stomach cancer	8.21e-05	0.000523	CcSEcCtD
Gliclazide—Gastrointestinal pain—Docetaxel—stomach cancer	8.19e-05	0.000523	CcSEcCtD
Gliclazide—Anaemia—Methotrexate—stomach cancer	8.18e-05	0.000522	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—stomach cancer	8.17e-05	0.000521	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—stomach cancer	8.16e-05	0.00052	CcSEcCtD
Gliclazide—Tension—Epirubicin—stomach cancer	8.13e-05	0.000518	CcSEcCtD
Gliclazide—Nervousness—Epirubicin—stomach cancer	8.04e-05	0.000513	CcSEcCtD
Gliclazide—Back pain—Epirubicin—stomach cancer	8.01e-05	0.000511	CcSEcCtD
Gliclazide—Feeling abnormal—Capecitabine—stomach cancer	8e-05	0.00051	CcSEcCtD
Gliclazide—Malaise—Methotrexate—stomach cancer	7.98e-05	0.000509	CcSEcCtD
Gliclazide—Gastrointestinal pain—Capecitabine—stomach cancer	7.93e-05	0.000506	CcSEcCtD
Gliclazide—Body temperature increased—Docetaxel—stomach cancer	7.92e-05	0.000505	CcSEcCtD
Gliclazide—Abdominal pain—Docetaxel—stomach cancer	7.92e-05	0.000505	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—stomach cancer	7.92e-05	0.000505	CcSEcCtD
Gliclazide—Chills—Doxorubicin—stomach cancer	7.9e-05	0.000504	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—stomach cancer	7.86e-05	0.000502	CcSEcCtD
Gliclazide—Cough—Methotrexate—stomach cancer	7.72e-05	0.000493	CcSEcCtD
Gliclazide—Mental disorder—Doxorubicin—stomach cancer	7.71e-05	0.000492	CcSEcCtD
Gliclazide—Urticaria—Capecitabine—stomach cancer	7.71e-05	0.000492	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—stomach cancer	7.68e-05	0.00049	CcSEcCtD
Gliclazide—Abdominal pain—Capecitabine—stomach cancer	7.67e-05	0.000489	CcSEcCtD
Gliclazide—Body temperature increased—Capecitabine—stomach cancer	7.67e-05	0.000489	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—stomach cancer	7.67e-05	0.000489	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—stomach cancer	7.66e-05	0.000489	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—stomach cancer	7.66e-05	0.000489	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—stomach cancer	7.65e-05	0.000488	CcSEcCtD
Gliclazide—Agitation—Epirubicin—stomach cancer	7.61e-05	0.000485	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—stomach cancer	7.55e-05	0.000482	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—stomach cancer	7.53e-05	0.000481	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—stomach cancer	7.53e-05	0.000481	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—stomach cancer	7.53e-05	0.000481	CcSEcCtD
Gliclazide—Tension—Doxorubicin—stomach cancer	7.52e-05	0.00048	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	7.48e-05	0.000477	CcSEcCtD
Gliclazide—Malaise—Epirubicin—stomach cancer	7.47e-05	0.000476	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—stomach cancer	7.44e-05	0.000475	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—stomach cancer	7.44e-05	0.000475	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—stomach cancer	7.41e-05	0.000473	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—stomach cancer	7.41e-05	0.000473	CcSEcCtD
Gliclazide—Hypersensitivity—Docetaxel—stomach cancer	7.38e-05	0.000471	CcSEcCtD
Gliclazide—Palpitations—Epirubicin—stomach cancer	7.32e-05	0.000467	CcSEcCtD
Gliclazide—Confusional state—Methotrexate—stomach cancer	7.28e-05	0.000464	CcSEcCtD
Gliclazide—Loss of consciousness—Epirubicin—stomach cancer	7.28e-05	0.000464	CcSEcCtD
Gliclazide—Cough—Epirubicin—stomach cancer	7.23e-05	0.000461	CcSEcCtD
Gliclazide—Asthenia—Docetaxel—stomach cancer	7.19e-05	0.000459	CcSEcCtD
Gliclazide—Convulsion—Epirubicin—stomach cancer	7.18e-05	0.000458	CcSEcCtD
Gliclazide—Infection—Methotrexate—stomach cancer	7.18e-05	0.000458	CcSEcCtD
Gliclazide—Hypertension—Epirubicin—stomach cancer	7.15e-05	0.000456	CcSEcCtD
Gliclazide—Hypersensitivity—Capecitabine—stomach cancer	7.15e-05	0.000456	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—stomach cancer	7.11e-05	0.000453	CcSEcCtD
Gliclazide—Pruritus—Docetaxel—stomach cancer	7.09e-05	0.000452	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—stomach cancer	7.08e-05	0.000452	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—stomach cancer	7.08e-05	0.000452	CcSEcCtD
Gliclazide—Thrombocytopenia—Methotrexate—stomach cancer	7.07e-05	0.000451	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—stomach cancer	7.05e-05	0.00045	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—stomach cancer	7.05e-05	0.00045	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—stomach cancer	7.05e-05	0.00045	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—stomach cancer	7.04e-05	0.000449	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—stomach cancer	7.03e-05	0.000448	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—stomach cancer	7.02e-05	0.000447	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	7e-05	0.000447	CcSEcCtD
Gliclazide—Hyperhidrosis—Methotrexate—stomach cancer	6.98e-05	0.000445	CcSEcCtD
Gliclazide—Discomfort—Epirubicin—stomach cancer	6.97e-05	0.000444	CcSEcCtD
Gliclazide—Asthenia—Capecitabine—stomach cancer	6.96e-05	0.000444	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—stomach cancer	6.91e-05	0.000441	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—stomach cancer	6.9e-05	0.00044	CcSEcCtD
Gliclazide—Pruritus—Capecitabine—stomach cancer	6.86e-05	0.000438	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—stomach cancer	6.86e-05	0.000437	CcSEcCtD
Gliclazide—Diarrhoea—Docetaxel—stomach cancer	6.86e-05	0.000437	CcSEcCtD
Gliclazide—Confusional state—Epirubicin—stomach cancer	6.82e-05	0.000435	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—stomach cancer	6.77e-05	0.000432	CcSEcCtD
Gliclazide—Hypotension—Methotrexate—stomach cancer	6.75e-05	0.00043	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—stomach cancer	6.74e-05	0.00043	CcSEcCtD
Gliclazide—Infection—Epirubicin—stomach cancer	6.71e-05	0.000428	CcSEcCtD
Gliclazide—Cough—Doxorubicin—stomach cancer	6.69e-05	0.000426	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—stomach cancer	6.64e-05	0.000423	CcSEcCtD
Gliclazide—Diarrhoea—Capecitabine—stomach cancer	6.64e-05	0.000423	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—stomach cancer	6.63e-05	0.000423	CcSEcCtD
Gliclazide—Dizziness—Docetaxel—stomach cancer	6.63e-05	0.000423	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—stomach cancer	6.62e-05	0.000422	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—stomach cancer	6.62e-05	0.000422	CcSEcCtD
Gliclazide—Tachycardia—Epirubicin—stomach cancer	6.6e-05	0.000421	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Methotrexate—stomach cancer	6.58e-05	0.00042	CcSEcCtD
Gliclazide—Skin disorder—Epirubicin—stomach cancer	6.57e-05	0.000419	CcSEcCtD
Gliclazide—Hyperhidrosis—Epirubicin—stomach cancer	6.53e-05	0.000417	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—stomach cancer	6.53e-05	0.000417	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—stomach cancer	6.52e-05	0.000416	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—stomach cancer	6.52e-05	0.000416	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—stomach cancer	6.52e-05	0.000416	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—stomach cancer	6.5e-05	0.000415	CcSEcCtD
Gliclazide—Paraesthesia—Methotrexate—stomach cancer	6.49e-05	0.000414	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	6.48e-05	0.000413	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—stomach cancer	6.45e-05	0.000411	CcSEcCtD
Gliclazide—Dyspnoea—Methotrexate—stomach cancer	6.44e-05	0.000411	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—stomach cancer	6.42e-05	0.00041	CcSEcCtD
Gliclazide—Dizziness—Capecitabine—stomach cancer	6.42e-05	0.000409	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—stomach cancer	6.38e-05	0.000407	CcSEcCtD
Gliclazide—Vomiting—Docetaxel—stomach cancer	6.37e-05	0.000406	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—stomach cancer	6.36e-05	0.000405	CcSEcCtD
Gliclazide—Rash—Docetaxel—stomach cancer	6.32e-05	0.000403	CcSEcCtD
Gliclazide—Hypotension—Epirubicin—stomach cancer	6.32e-05	0.000403	CcSEcCtD
Gliclazide—Dermatitis—Docetaxel—stomach cancer	6.31e-05	0.000403	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—stomach cancer	6.31e-05	0.000402	CcSEcCtD
Gliclazide—Headache—Docetaxel—stomach cancer	6.28e-05	0.0004	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Methotrexate—stomach cancer	6.24e-05	0.000398	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—stomach cancer	6.23e-05	0.000397	CcSEcCtD
Gliclazide—Infection—Doxorubicin—stomach cancer	6.21e-05	0.000396	CcSEcCtD
Gliclazide—Pain—Methotrexate—stomach cancer	6.18e-05	0.000394	CcSEcCtD
Gliclazide—Vomiting—Capecitabine—stomach cancer	6.17e-05	0.000393	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—stomach cancer	6.16e-05	0.000393	CcSEcCtD
Gliclazide—Nervous system disorder—Doxorubicin—stomach cancer	6.13e-05	0.000391	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—stomach cancer	6.12e-05	0.000391	CcSEcCtD
Gliclazide—Rash—Capecitabine—stomach cancer	6.12e-05	0.00039	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—stomach cancer	6.11e-05	0.00039	CcSEcCtD
Gliclazide—Dermatitis—Capecitabine—stomach cancer	6.11e-05	0.00039	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—stomach cancer	6.1e-05	0.000389	CcSEcCtD
Gliclazide—Headache—Capecitabine—stomach cancer	6.08e-05	0.000388	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—stomach cancer	6.07e-05	0.000387	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—stomach cancer	6.07e-05	0.000387	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—stomach cancer	6.05e-05	0.000386	CcSEcCtD
Gliclazide—Dyspnoea—Epirubicin—stomach cancer	6.03e-05	0.000384	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—stomach cancer	6.01e-05	0.000383	CcSEcCtD
Gliclazide—Nausea—Docetaxel—stomach cancer	5.95e-05	0.00038	CcSEcCtD
Gliclazide—Feeling abnormal—Methotrexate—stomach cancer	5.95e-05	0.00038	CcSEcCtD
Gliclazide—Dyspepsia—Epirubicin—stomach cancer	5.95e-05	0.000379	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—stomach cancer	5.91e-05	0.000377	CcSEcCtD
Gliclazide—Hypotension—Doxorubicin—stomach cancer	5.84e-05	0.000373	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Epirubicin—stomach cancer	5.84e-05	0.000372	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—stomach cancer	5.83e-05	0.000372	CcSEcCtD
Gliclazide—Pain—Epirubicin—stomach cancer	5.78e-05	0.000369	CcSEcCtD
Gliclazide—Constipation—Epirubicin—stomach cancer	5.78e-05	0.000369	CcSEcCtD
Gliclazide—Nausea—Capecitabine—stomach cancer	5.76e-05	0.000368	CcSEcCtD
Gliclazide—Urticaria—Methotrexate—stomach cancer	5.74e-05	0.000366	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—stomach cancer	5.71e-05	0.000364	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—stomach cancer	5.71e-05	0.000364	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—stomach cancer	5.7e-05	0.000363	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—stomach cancer	5.66e-05	0.000361	CcSEcCtD
Gliclazide—Paraesthesia—Doxorubicin—stomach cancer	5.62e-05	0.000358	CcSEcCtD
Gliclazide—Dyspnoea—Doxorubicin—stomach cancer	5.58e-05	0.000356	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—stomach cancer	5.57e-05	0.000355	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—stomach cancer	5.56e-05	0.000355	CcSEcCtD
Gliclazide—Gastrointestinal pain—Epirubicin—stomach cancer	5.53e-05	0.000353	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—stomach cancer	5.51e-05	0.000351	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Doxorubicin—stomach cancer	5.4e-05	0.000344	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—stomach cancer	5.39e-05	0.000344	CcSEcCtD
Gliclazide—Urticaria—Epirubicin—stomach cancer	5.37e-05	0.000342	CcSEcCtD
Gliclazide—Pain—Doxorubicin—stomach cancer	5.35e-05	0.000341	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—stomach cancer	5.35e-05	0.000341	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—stomach cancer	5.34e-05	0.000341	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—stomach cancer	5.34e-05	0.000341	CcSEcCtD
Gliclazide—Hypersensitivity—Methotrexate—stomach cancer	5.32e-05	0.000339	CcSEcCtD
Gliclazide—Asthenia—Methotrexate—stomach cancer	5.18e-05	0.00033	CcSEcCtD
Gliclazide—Feeling abnormal—Doxorubicin—stomach cancer	5.15e-05	0.000329	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—stomach cancer	5.11e-05	0.000326	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—stomach cancer	5.11e-05	0.000326	CcSEcCtD
Gliclazide—Hypersensitivity—Epirubicin—stomach cancer	4.98e-05	0.000318	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—stomach cancer	4.97e-05	0.000317	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—stomach cancer	4.94e-05	0.000315	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—stomach cancer	4.94e-05	0.000315	CcSEcCtD
Gliclazide—Diarrhoea—Methotrexate—stomach cancer	4.94e-05	0.000315	CcSEcCtD
Gliclazide—Asthenia—Epirubicin—stomach cancer	4.85e-05	0.000309	CcSEcCtD
Gliclazide—Pruritus—Epirubicin—stomach cancer	4.78e-05	0.000305	CcSEcCtD
Gliclazide—Dizziness—Methotrexate—stomach cancer	4.78e-05	0.000305	CcSEcCtD
Gliclazide—Diarrhoea—Epirubicin—stomach cancer	4.62e-05	0.000295	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—stomach cancer	4.61e-05	0.000294	CcSEcCtD
Gliclazide—Vomiting—Methotrexate—stomach cancer	4.59e-05	0.000293	CcSEcCtD
Gliclazide—Rash—Methotrexate—stomach cancer	4.55e-05	0.00029	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—stomach cancer	4.55e-05	0.00029	CcSEcCtD
Gliclazide—Headache—Methotrexate—stomach cancer	4.52e-05	0.000289	CcSEcCtD
Gliclazide—Asthenia—Doxorubicin—stomach cancer	4.49e-05	0.000286	CcSEcCtD
Gliclazide—Dizziness—Epirubicin—stomach cancer	4.47e-05	0.000285	CcSEcCtD
Gliclazide—Pruritus—Doxorubicin—stomach cancer	4.42e-05	0.000282	CcSEcCtD
Gliclazide—Vomiting—Epirubicin—stomach cancer	4.3e-05	0.000274	CcSEcCtD
Gliclazide—Nausea—Methotrexate—stomach cancer	4.29e-05	0.000274	CcSEcCtD
Gliclazide—Diarrhoea—Doxorubicin—stomach cancer	4.28e-05	0.000273	CcSEcCtD
Gliclazide—Rash—Epirubicin—stomach cancer	4.26e-05	0.000272	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—stomach cancer	4.26e-05	0.000272	CcSEcCtD
Gliclazide—Headache—Epirubicin—stomach cancer	4.23e-05	0.00027	CcSEcCtD
Gliclazide—Dizziness—Doxorubicin—stomach cancer	4.14e-05	0.000264	CcSEcCtD
Gliclazide—Nausea—Epirubicin—stomach cancer	4.01e-05	0.000256	CcSEcCtD
Gliclazide—Vomiting—Doxorubicin—stomach cancer	3.98e-05	0.000254	CcSEcCtD
Gliclazide—Rash—Doxorubicin—stomach cancer	3.94e-05	0.000251	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—stomach cancer	3.94e-05	0.000251	CcSEcCtD
Gliclazide—Headache—Doxorubicin—stomach cancer	3.92e-05	0.00025	CcSEcCtD
Gliclazide—Nausea—Doxorubicin—stomach cancer	3.71e-05	0.000237	CcSEcCtD
Gliclazide—CYP2C9—Metabolism—NDUFV1—stomach cancer	2.38e-05	0.000226	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NDUFS1—stomach cancer	2.38e-05	0.000226	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—AKR1C3—stomach cancer	2.38e-05	0.000226	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTP1—stomach cancer	2.37e-05	0.000225	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPP2R1A—stomach cancer	2.34e-05	0.000223	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—HMOX1—stomach cancer	2.33e-05	0.000222	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PGLS—stomach cancer	2.33e-05	0.000221	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—BLVRB—stomach cancer	2.33e-05	0.000221	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5—stomach cancer	2.33e-05	0.000221	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ADRB1—stomach cancer	2.32e-05	0.000221	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTP1—stomach cancer	2.3e-05	0.000218	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—HMOX1—stomach cancer	2.26e-05	0.000215	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CD44—stomach cancer	2.26e-05	0.000215	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—HRAS—stomach cancer	2.25e-05	0.000214	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPAP2A—stomach cancer	2.22e-05	0.000211	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RPS6—stomach cancer	2.22e-05	0.000211	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NDUFA2—stomach cancer	2.2e-05	0.00021	CbGpPWpGaD
Gliclazide—ALB—Metabolism—FBP1—stomach cancer	2.2e-05	0.00021	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CA1—stomach cancer	2.2e-05	0.00021	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CKB—stomach cancer	2.2e-05	0.00021	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—TYMS—stomach cancer	2.2e-05	0.000209	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—STAT3—stomach cancer	2.2e-05	0.000209	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTM1—stomach cancer	2.18e-05	0.000207	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SERPINE1—stomach cancer	2.17e-05	0.000206	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL6—stomach cancer	2.15e-05	0.000205	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6—stomach cancer	2.15e-05	0.000205	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—stomach cancer	2.13e-05	0.000203	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—TYMS—stomach cancer	2.13e-05	0.000203	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PGLS—stomach cancer	2.12e-05	0.000202	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—BLVRB—stomach cancer	2.12e-05	0.000202	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTM1—stomach cancer	2.11e-05	0.000201	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MAPK3—stomach cancer	2.1e-05	0.0002	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—RHOA—stomach cancer	2.09e-05	0.000199	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLIN2—stomach cancer	2.07e-05	0.000197	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—MAPK3—stomach cancer	2.06e-05	0.000196	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ERCC2—stomach cancer	2.05e-05	0.000195	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HBEGF—stomach cancer	2.04e-05	0.000194	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPAP2A—stomach cancer	2.02e-05	0.000192	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CA2—stomach cancer	2.02e-05	0.000192	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MAPK1—stomach cancer	2e-05	0.00019	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EGFR—stomach cancer	2e-05	0.00019	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ERCC2—stomach cancer	1.98e-05	0.000189	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NDUFA2—stomach cancer	1.98e-05	0.000188	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CKB—stomach cancer	1.98e-05	0.000188	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CA1—stomach cancer	1.98e-05	0.000188	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—FBP1—stomach cancer	1.98e-05	0.000188	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PGAM1—stomach cancer	1.96e-05	0.000187	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NT5E—stomach cancer	1.96e-05	0.000187	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—MAPK1—stomach cancer	1.96e-05	0.000186	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—stomach cancer	1.95e-05	0.000185	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—MTHFR—stomach cancer	1.92e-05	0.000183	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PPP2R1A—stomach cancer	1.92e-05	0.000183	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—stomach cancer	1.9e-05	0.000181	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—stomach cancer	1.89e-05	0.000179	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ADRB2—stomach cancer	1.88e-05	0.000179	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALDH7A1—stomach cancer	1.87e-05	0.000178	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLCE1—stomach cancer	1.87e-05	0.000178	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—MTHFR—stomach cancer	1.86e-05	0.000177	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLIN2—stomach cancer	1.86e-05	0.000177	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—stomach cancer	1.85e-05	0.000176	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PPP2R1A—stomach cancer	1.84e-05	0.000175	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CA2—stomach cancer	1.81e-05	0.000172	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—FBP1—stomach cancer	1.8e-05	0.000172	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NDUFA2—stomach cancer	1.8e-05	0.000172	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CKB—stomach cancer	1.8e-05	0.000172	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CA1—stomach cancer	1.8e-05	0.000172	CbGpPWpGaD
Gliclazide—ALB—Metabolism—UMPS—stomach cancer	1.8e-05	0.000171	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CAV1—stomach cancer	1.77e-05	0.000169	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—APOA1—stomach cancer	1.77e-05	0.000168	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NT5E—stomach cancer	1.76e-05	0.000168	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PGAM1—stomach cancer	1.76e-05	0.000168	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CAV1—stomach cancer	1.72e-05	0.000164	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—APOA1—stomach cancer	1.72e-05	0.000163	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SMAD4—stomach cancer	1.71e-05	0.000163	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CA—stomach cancer	1.7e-05	0.000162	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLIN2—stomach cancer	1.7e-05	0.000161	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—FYN—stomach cancer	1.69e-05	0.000161	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALDH7A1—stomach cancer	1.68e-05	0.00016	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLCE1—stomach cancer	1.68e-05	0.00016	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PDHA1—stomach cancer	1.67e-05	0.000159	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ECHS1—stomach cancer	1.67e-05	0.000159	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CA2—stomach cancer	1.65e-05	0.000157	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—stomach cancer	1.64e-05	0.000156	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FYN—stomach cancer	1.63e-05	0.000155	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—UMPS—stomach cancer	1.61e-05	0.000153	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NT5E—stomach cancer	1.61e-05	0.000153	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PGAM1—stomach cancer	1.61e-05	0.000153	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—HMOX1—stomach cancer	1.61e-05	0.000153	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—stomach cancer	1.6e-05	0.000153	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—stomach cancer	1.57e-05	0.00015	CbGpPWpGaD
Gliclazide—ALB—Metabolism—FADS1—stomach cancer	1.57e-05	0.000149	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMP—stomach cancer	1.57e-05	0.000149	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPARG—stomach cancer	1.56e-05	0.000148	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—stomach cancer	1.53e-05	0.000146	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLCE1—stomach cancer	1.53e-05	0.000146	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALDH7A1—stomach cancer	1.53e-05	0.000146	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGFR2—stomach cancer	1.53e-05	0.000145	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPARG—stomach cancer	1.51e-05	0.000144	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ECHS1—stomach cancer	1.5e-05	0.000143	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PDHA1—stomach cancer	1.5e-05	0.000143	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—stomach cancer	1.49e-05	0.000142	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—UMPS—stomach cancer	1.47e-05	0.00014	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SREBF2—stomach cancer	1.47e-05	0.00014	CbGpPWpGaD
Gliclazide—ALB—Metabolism—RORA—stomach cancer	1.45e-05	0.000138	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PLAU—stomach cancer	1.44e-05	0.000137	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CAV1—stomach cancer	1.41e-05	0.000134	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK3—stomach cancer	1.41e-05	0.000134	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—FADS1—stomach cancer	1.41e-05	0.000134	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMP—stomach cancer	1.41e-05	0.000134	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—APOA1—stomach cancer	1.41e-05	0.000134	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—stomach cancer	1.4e-05	0.000133	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IRS2—stomach cancer	1.4e-05	0.000133	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PDHA1—stomach cancer	1.37e-05	0.00013	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ECHS1—stomach cancer	1.37e-05	0.00013	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALDOB—stomach cancer	1.36e-05	0.000129	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—stomach cancer	1.36e-05	0.000129	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CAV1—stomach cancer	1.35e-05	0.000129	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APOA1—stomach cancer	1.35e-05	0.000129	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PRKCB—stomach cancer	1.34e-05	0.000128	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK1—stomach cancer	1.34e-05	0.000128	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NOS3—stomach cancer	1.34e-05	0.000128	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SREBF2—stomach cancer	1.32e-05	0.000126	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—RORA—stomach cancer	1.3e-05	0.000124	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NOS3—stomach cancer	1.3e-05	0.000124	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PRKCB—stomach cancer	1.29e-05	0.000123	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—FADS1—stomach cancer	1.29e-05	0.000122	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMP—stomach cancer	1.29e-05	0.000122	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6ST—stomach cancer	1.28e-05	0.000122	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CAV1—stomach cancer	1.28e-05	0.000122	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—APOA1—stomach cancer	1.28e-05	0.000122	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALOX5—stomach cancer	1.27e-05	0.00012	CbGpPWpGaD
Gliclazide—ALB—Metabolism—DPYD—stomach cancer	1.25e-05	0.000118	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APC—stomach cancer	1.23e-05	0.000117	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—stomach cancer	1.23e-05	0.000117	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALDOB—stomach cancer	1.22e-05	0.000116	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—APOA1—stomach cancer	1.22e-05	0.000116	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SREBF2—stomach cancer	1.2e-05	0.000114	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—RORA—stomach cancer	1.19e-05	0.000113	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—stomach cancer	1.19e-05	0.000113	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—stomach cancer	1.16e-05	0.000111	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—stomach cancer	1.15e-05	0.00011	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—stomach cancer	1.15e-05	0.000109	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6R—stomach cancer	1.15e-05	0.000109	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALOX5—stomach cancer	1.14e-05	0.000108	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	1.13e-05	0.000107	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—DPYD—stomach cancer	1.12e-05	0.000106	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SERPINE1—stomach cancer	1.12e-05	0.000106	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALDOB—stomach cancer	1.11e-05	0.000106	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTT1—stomach cancer	1.1e-05	0.000105	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP2A6—stomach cancer	1.09e-05	0.000104	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RHOA—stomach cancer	1.08e-05	0.000102	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SERPINE1—stomach cancer	1.07e-05	0.000102	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS3—stomach cancer	1.07e-05	0.000101	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKR1C3—stomach cancer	1.06e-05	0.000101	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—stomach cancer	1.05e-05	0.0001	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—stomach cancer	1.05e-05	9.97e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALOX5—stomach cancer	1.04e-05	9.85e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RHOA—stomach cancer	1.03e-05	9.84e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ENO1—stomach cancer	1.03e-05	9.81e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOS3—stomach cancer	1.02e-05	9.74e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—DPYD—stomach cancer	1.02e-05	9.69e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	1.01e-05	9.64e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTT1—stomach cancer	9.88e-06	9.4e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP2A6—stomach cancer	9.77e-06	9.29e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB2—stomach cancer	9.58e-06	9.11e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKR1C3—stomach cancer	9.5e-06	9.04e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ENO1—stomach cancer	9.26e-06	8.81e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	9.24e-06	8.79e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CD44—stomach cancer	9.15e-06	8.7e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—stomach cancer	9.11e-06	8.67e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—stomach cancer	9.09e-06	8.64e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTT1—stomach cancer	9.01e-06	8.57e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2A6—stomach cancer	8.91e-06	8.47e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	8.88e-06	8.44e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1B—stomach cancer	8.87e-06	8.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKR1C3—stomach cancer	8.67e-06	8.24e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—stomach cancer	8.46e-06	8.05e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUN—stomach cancer	8.45e-06	8.03e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ENO1—stomach cancer	8.45e-06	8.03e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—stomach cancer	8.31e-06	7.9e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—stomach cancer	8.22e-06	7.82e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CD44—stomach cancer	8.21e-06	7.81e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1A—stomach cancer	8.19e-06	7.79e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK8—stomach cancer	7.99e-06	7.6e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	7.97e-06	7.58e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPP2R1A—stomach cancer	7.78e-06	7.4e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—stomach cancer	7.68e-06	7.31e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTP1—stomach cancer	7.63e-06	7.26e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—stomach cancer	7.54e-06	7.18e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HMOX1—stomach cancer	7.53e-06	7.16e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CD44—stomach cancer	7.49e-06	7.12e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—stomach cancer	7.32e-06	6.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—stomach cancer	7.31e-06	6.95e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	7.27e-06	6.91e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK3—stomach cancer	7.27e-06	6.91e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMS—stomach cancer	7.1e-06	6.75e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTM1—stomach cancer	7.01e-06	6.67e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPP2R1A—stomach cancer	6.98e-06	6.64e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK3—stomach cancer	6.98e-06	6.64e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK1—stomach cancer	6.91e-06	6.58e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTP1—stomach cancer	6.85e-06	6.52e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—stomach cancer	6.79e-06	6.46e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HMOX1—stomach cancer	6.76e-06	6.43e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK1—stomach cancer	6.64e-06	6.32e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—stomach cancer	6.64e-06	6.32e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ERCC2—stomach cancer	6.59e-06	6.27e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—stomach cancer	6.53e-06	6.21e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMS—stomach cancer	6.37e-06	6.06e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPP2R1A—stomach cancer	6.37e-06	6.06e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTM1—stomach cancer	6.3e-06	5.99e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—stomach cancer	6.27e-06	5.97e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTP1—stomach cancer	6.25e-06	5.94e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTHFR—stomach cancer	6.2e-06	5.9e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HMOX1—stomach cancer	6.16e-06	5.86e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—stomach cancer	6e-06	5.71e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ERCC2—stomach cancer	5.92e-06	5.63e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMS—stomach cancer	5.81e-06	5.52e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—stomach cancer	5.8e-06	5.52e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—stomach cancer	5.76e-06	5.48e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTM1—stomach cancer	5.74e-06	5.46e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CAV1—stomach cancer	5.72e-06	5.44e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOA1—stomach cancer	5.7e-06	5.43e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—stomach cancer	5.58e-06	5.3e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTHFR—stomach cancer	5.56e-06	5.29e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—stomach cancer	5.55e-06	5.28e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	5.46e-06	5.2e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ERCC2—stomach cancer	5.4e-06	5.13e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—stomach cancer	5.33e-06	5.07e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CAV1—stomach cancer	5.13e-06	4.88e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOA1—stomach cancer	5.12e-06	4.87e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—stomach cancer	5.1e-06	4.85e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTHFR—stomach cancer	5.07e-06	4.83e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARG—stomach cancer	5.03e-06	4.78e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	4.9e-06	4.66e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CAV1—stomach cancer	4.68e-06	4.45e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOA1—stomach cancer	4.67e-06	4.44e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARG—stomach cancer	4.51e-06	4.29e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	4.47e-06	4.25e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NOS3—stomach cancer	4.32e-06	4.11e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARG—stomach cancer	4.11e-06	3.91e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—stomach cancer	4.06e-06	3.86e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—stomach cancer	3.95e-06	3.76e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NOS3—stomach cancer	3.88e-06	3.69e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—stomach cancer	3.7e-06	3.52e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—stomach cancer	3.55e-06	3.38e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NOS3—stomach cancer	3.54e-06	3.37e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—stomach cancer	3.24e-06	3.08e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—stomach cancer	2.43e-06	2.31e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—stomach cancer	2.18e-06	2.08e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—stomach cancer	1.99e-06	1.89e-05	CbGpPWpGaD
